AI Article Synopsis
- The study focuses on the effectiveness of enterocin DD14 (EntDD14) against methicillin-resistant Staphylococcus aureus (MRSA) strains, both alone and in combination with antibiotics.
- EntDD14 significantly reduces the adhesion of MRSA to human cells, demonstrating its potential as a therapeutic agent.
- Additionally, EntDD14 shows an anti-inflammatory effect by decreasing the secretion of pro-inflammatory interleukins IL-6 and IL-8, suggesting its dual role in fighting bacterial infections and limiting inflammation.
Article Abstract
In this study, we investigate the interactions between the leaderless class IIb bacteriocin, enterocin DD14 (EntDD14), or the methicillin or the combination of these antibacterials, and two methicillin-resistant Staphylococcus aureus strains (MRSA-S1 and USA 300) which are respectively a clinical strain and a reference strain. The results obtained showed that EntDD14 alone or in combination with the antibiotic could significantly prevent the adhesion of these pathogenic bacteria to human cells. On the other hand, we investigated the anti-inflammatory effect of EntDD14 on the secretion of pro-inflammatory interleukins, including IL-6 and IL-8. The results show that EntDD14 is able to decrease significantly the secretion of both interleukins on Caco-2 cells following their treatments with lipopolysaccharides. These novel data provide insightful informations to support applications of bacteriocins as therapeutic agents capable as well to defeat pathogenic bacteria and concomitantly limit their inflammatory reactions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125348 | PMC |
| http://dx.doi.org/10.1007/s12602-022-09954-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!